What the Portfolio Review Letter Writer actually produces

[Date] Margaret & Thomas Ellison [Address] Dear Margaret and Thomas, I'm pleased to share your quarterly portfolio review for the period ended March 31, 2025. Your portfolio delivered solid returns during a quarter marked by cautious optimism in equities and steady performance in fixed income. Thank you for your continued trust and partnership. PORTFOLIO PERFORMANCE Your portfolio returned 4.7% for the quarter, outperforming your blended benchmark by 112 basis points. This outperformance was driven primarily by strategic overweights in healthcare and industrials within your equity sleeve, which gained 6.2% during the period. Your fixed income allocation contributed steadily with a 2.1% return, while alternatives remained relatively flat at 0.3%. Your total portfolio value as of March 31, 2025 stands at $1,284,500, up $58,400 from year-end 2024 — a meaningful start to the year. QUARTER IN CONTEXT The first quarter of 2025 saw continued resilience in U.S. equities despite mixed inflation signals and Federal Reserve commentary hinting at a cautious approach to future rate cuts. The 10-year Treasury yield fluctuated in a range but ultimately settled near 4.3% at quarter-end, providing a steady foundation for fixed income returns. International developed markets lagged the U.S., while emerging markets posted modest gains supported by a softer U.S. dollar. Corporate credit spreads remained tight, benefiting bond holders. ACTIONS TAKEN ON YOUR BEHALF During the quarter, we executed a tactical adjustment to capture gains and reposition for the current market environment. Specifically, we trimmed your technology overweight from 18% to 14% of your equity sleeve, locking in strong gains from 2024. We redeployed those proceeds into healthcare (increased from 10% to 13%) and established a new position in a short-duration investment-grade bond ETF, adding approximately $38,000. This adjustment modestly increased diversification and is consistent with our view of near-term market conditions. Your overall target allocation of 62% equities, 30% fixed income, and 8% alternatives remains unchanged and appropriate for your moderate growth profile. OUTLOOK AND POSITIONING Looking ahead, we expect continued volatility tied to inflation data and Federal Reserve policy. We view the current portfolio positioning as well-balanced for these conditions: your equity sleeve has exposure to economically resilient sectors (healthcare, industrials) while your fixed income allocation provides ballast and income. We will continue to monitor our overweight positions and any material shifts in the economic backdrop. I'd welcome the opportunity to sit down with you in the coming weeks to discuss the quarter, address any questions, and confirm that your current allocation and strategy remain aligned with your goals. Please let me know a time that works for you. Thank you for your continued confidence. Warm regards, [Advisor Name] [Title] [Contact Info]

PORTFOLIO PERFORMANCE | Quarter Return (Absolute): +4.7% | Quarter Return (vs. Benchmark): +112 bps | Benchmark Return: +3.58% | Year-to-Date Return: +4.7% | Portfolio Value (3/31/2025): $1,284,500 | Portfolio Value (12/31/2024): $1,226,100 ASSET CLASS PERFORMANCE | Equities: +6.2% | Fixed Income: +2.1% | Alternatives: +0.3% NOTABLE CONTRIBUTORS & DETRACTORS | Top Contributor: Healthcare sector overweight (outperformed benchmark by 150+ bps) | Second Contributor: Industrials sector positioning | Detractor: Technology sector trim locked in 2024 gains but underperformed in early Q1 rally | Fixed Income Anchor: Corporate credit spreads compressed, supporting bond returns REBALANCING ACTIVITY | Technology overweight reduction: 18% → 14% (proceeds redeployed) | Healthcare increase: 10% → 13% | New Position: Short-duration investment-grade bond ETF (~$38K) | Target Allocation Maintained: 62% equities / 30% fixed income / 8% alternatives

We anticipate continued market volatility in Q2 2025, with key drivers being inflation print data, Federal Reserve messaging on rate-cut timing, and corporate earnings resilience. While U.S. equities have shown underlying strength, we recommend managing expectations for outsized gains in the near term and preparing for potential 5–10% pullbacks as a normal market occurrence. Your current portfolio positioning is well-suited to this environment. The healthcare and industrials overweights provide exposure to sectors with more stable cash flows and less sensitivity to interest-rate fears, while your fixed income allocation acts as a stabilizer. We will continue to monitor whether spreads and yield opportunities present attractive tactical opportunities for rebalancing or selective additions. Looking further ahead, we believe a diversified, disciplined approach — rebalancing annually and avoiding reactive changes — will serve you well. We will maintain our watchlist on any material shifts in Fed policy, inflation readings, or geopolitical developments and will reach out proactively should we recommend meaningful adjustments to your allocation.